Advertisement

Role of inflammation in the pathogenesis and treatment of fibromyalgia

  • Ilke Coskun BenlidayiEmail author
Review

Abstract

Fibromyalgia is a multifaceted disease. The clinical picture of fibromyalgia covers numerous comorbidities. Each comorbidity stands as a distinct condition. However, common pathophysiologic factors are occupied in their background. Along with the genetic, environmental and neuro-hormonal factors, inflammation has been supposed to have role in the pathogenesis of fibromyalgia. The aim of the present article was to review the current literature regarding the potential role of inflammation in the pathogenesis and treatment of fibromyalgia. A literature search was conducted through PubMed/MEDLINE and Web of Science databases using relevant keywords. Recent evidence on this highly studied topic indicates that fibromyalgia has an immunological background. Cytokines/chemokines, lipid mediators, oxidative stress and several plasma-derived factors underlie the inflammatory state in fibromyalgia. There are potential new therapeutic options targeting inflammatory pathways in fibromyalgia patients. In conclusion, there is evidence to support the inflammation-driven pathways in the pathogenesis of fibromyalgia. However, further research is required to fully understand the network of inflammation and its possible role in diagnosis and/or treatment of fibromyalgia.

Keywords

Cytokines Fibromyalgia Inflammation Inflammatory markers Neurogenic inflammation Treatment 

Notes

Author contributions

ICB contributed to the conception and design of the study; collection and interpretation of data; drafting and revising the article; and approval of the final version.

Funding

None.

Compliance with ethical standards

Conflict of interest

The author declares that she has no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by the author.

References

  1. 1.
    Clauw DJ (2019) Fibromyalgia and related syndromes. In: Hochberg MC, Gravallese EM, Silman AJ, Smoşen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 736–745Google Scholar
  2. 2.
    Mastrangelo F, Frydas I, Ronconi G, Kritas SK, Tettamanti L, Caraffa A, D Ovidio C, Younes A, Gallenga CE, Conti P (2018) Low-grade chronic inflammation mediate by mast cells in fibromyalgia: role of IL-37. J Biol Regul Homeost Agents 32:195–198Google Scholar
  3. 3.
    Coskun Benlidayi I (2018) Fibromyalgia as a challenge for patients and physicians. Rheumatol Int 38:2345.  https://doi.org/10.1007/s00296-018-4138-4136 Google Scholar
  4. 4.
    Kozanoglu E, Coskun Benlidayi I, Eker Akilli R, Tasal A (2016) Is there any link between joint hypermobility and mitral valve prolapse in patients with fibromyalgia syndrome? Clin Rheumatol 35:1041–1044.  https://doi.org/10.1007/s10067-015-3024-3029 Google Scholar
  5. 5.
    Ramírez-Tejero JA, Martínez-Lara E, Rus A, Camacho MV, Del Moral ML, Siles E (2018) Insight into the biological pathways underlying fibromyalgia by a proteomic approach (. J Proteomics 186:47–55.  https://doi.org/10.1016/j.jprot.2018.07.009 Google Scholar
  6. 6.
    Sluka KA, Clauw DJ (2016) Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience 338:114–129.  https://doi.org/10.1016/j.neuroscience.2016.06.006 Google Scholar
  7. 7.
    Littlejohn G, Guymer E (2018) Neurogenic inflammation in fibromyalgia. Semin Immunopathol 40:291–300.  https://doi.org/10.1007/s00281-018-0672-2 Google Scholar
  8. 8.
    Metyas S, Rezk T, Arkfeld D, Leptich T (2017) Autoinflammation and immunomodulation in inflammatory fibromyalgia syndrome- a review. Curr Rheumatol Rev 13:98–102.  https://doi.org/10.2174/1573397112666160919120530 Google Scholar
  9. 9.
    Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E (2012) Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels (. J Neuroimmunol 242:33–38.  https://doi.org/10.1016/j.jneuroim.2011.10.013 Google Scholar
  10. 10.
    Kosek E, Altawil R, Kadetoff D, Finn A, Westman M, Le Maître E, Andersson M, Jensen-Urstad M, Lampa J (2015) Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain-interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. J Neuroimmunol 280:49–55.  https://doi.org/10.1016/j.jneuroim.2015.02.002 Google Scholar
  11. 11.
    Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, Pérez-Tapia SM, Pérez-Sánchez G, Garcés-Alvarez ME, Aguirre-Cruz L, Velasco-Velázquez MA, Pavón L (2016) IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol 290:22–25.  https://doi.org/10.1016/j.jneuroim.2015.11.011 Google Scholar
  12. 12.
    Malhotra D, Saxena AK, Dar SA, Kumar V, Nasare N, Tripathi AK, Banerjee BD (2012) Evaluation of cytokine levels in fibromyalgia syndrome patients and its relationship to the severity of chronic pain. J Musculoskelet Pain 20:164–169.  https://doi.org/10.3109/10582452.2012.704141 Google Scholar
  13. 13.
    Bote ME, García JJ, Hinchado MD, Ortega E (2012) Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 19:343–351.  https://doi.org/10.1159/000341664 Google Scholar
  14. 14.
    Imamura M, Targino RA, Hsing WT, Imamura S, Azevedo RS, Boas LS, Tozetto-Mendoza TR, Alfieri FM, Filippo TR, Battistella LR (2014) Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia. Clin Interv Aging 9:939–944.  https://doi.org/10.2147/CIA.S60330 Google Scholar
  15. 15.
    Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417.  https://doi.org/10.1007/s00296-011-1999-3 Google Scholar
  16. 16.
    Manicone AM, McGuire JK (2008) Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19:34–41Google Scholar
  17. 17.
    Porth CM (2011) Inflammation, the inflammatory response and fever. In: Porth CM (ed) Essentials of pathophysiology, 3rd edn. Wolters Kluwer Health|Lippincott Williams & Wilkins, China, pp 51–72Google Scholar
  18. 18.
    Bjurstrom MF, Giron SE, Griffis CA (2016) Cerebrospinal fluid cytokines and neurotrophic factors in human chronic pain populations: a comprehensive review. Pain Pract 16:183–203.  https://doi.org/10.1111/papr.12252 Google Scholar
  19. 19.
    Christidis N, Ghafouri B, Larsson A, Palstam A, Mannerkorpi K, Bileviciute-Ljungar I, Löfgren M, Bjersing J, Kosek E, Gerdle B, Ernberg M (2015) Comparison of the levels of pro-inflammatory cytokines released in the vastus lateralis muscle of patients with fibromyalgia and healthy controls during contractions of the quadriceps muscle—a microdialysis study. PLoS One 10:e0143856.  https://doi.org/10.1371/journal.pone.0143856 Google Scholar
  20. 20.
    Feng J, Zhang Z, Wu X, Mao A, Chang F, Deng X, Gao H, Ouyang C, Dery KJ, Le K, Longmate J, Marek C, St Amand RP, Krontiris TG, Shively JE (2013) Discovery of potential new gene variants and inflammatory cytokine associations with fibromyalgia syndrome by whole exome sequencing. PLoS One 8:e65033.  https://doi.org/10.1371/journal.pone.0065033 Google Scholar
  21. 21.
    Smith SB, Maixner DW, Fillingim RB, Slade G, Gracely RH, Ambrose K, Zaykin DV, Hyde C, John S, Tan K, Maixner W, Diatchenko L (2012) Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum 64:584–593.  https://doi.org/10.1002/art.33338 Google Scholar
  22. 22.
    Iacob E, Light AR, Donaldson GW, Okifuji A, Hughen RW, White AT, Light KC (2016) Gene expression factor analysis to differentiate pathways linked to fibromyalgia, chronic fatigue syndrome, and depression in a diverse patient sample. Arthritis Care Res (Hoboken) 68:132–140.  https://doi.org/10.1002/acr.22639 Google Scholar
  23. 23.
    Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, Kapczinski F, Xavier RM (2016) Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia—a controlled cross-sectional study. Cytokine 84:25–28.  https://doi.org/10.1016/j.cyto.2016.05.011 Google Scholar
  24. 24.
    Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, Reis D (2013) Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 31(6 Suppl 79):S60-63Google Scholar
  25. 25.
    Xiao Y, Haynes WL, Michalek JE, Russell IJ (2013) Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 33:1259–1264.  https://doi.org/10.1007/s00296-012-2538-6 Google Scholar
  26. 26.
    Behm FG, Gavin IM, Karpenko O, Lindgren V, Gaitonde S, Gashkoff PA, Gillis BS (2012) Unique immunologic patterns in fibromyalgia. BMC Clin Pathol 12:25.  https://doi.org/10.1186/1472-6890-12-25 Google Scholar
  27. 27.
    Sturgill J, McGee E, Menzies V (2014) Unique cytokine signature in the plasma of patients with fibromyalgia. J Immunol Res 2014:938576.  https://doi.org/10.1155/2014/938576 Google Scholar
  28. 28.
    Tsilioni I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356:664–672.  https://doi.org/10.1124/jpet.115.230060 Google Scholar
  29. 29.
    Iannuccelli C, Guzzo MP, Atzeni F, Mannocci F, Alessandri C, Gerardi MC, Valesini G, Di Franco M (2017) Pain modulation in patients with fibromyalgia undergoing acupuncture treatment is associated with fluctuations in serum neuropeptide Y levels. Clin Exp Rheumatol 105:81–85Google Scholar
  30. 30.
    Taylor AG, Fischer-White TG, Anderson JG, Adelstein KE, Murugesan M, Lewis JE, Scott MM, Gaykema RP, Goehler LE (2016) Stress, inflammation and pain: a potential role for monocytes in fibromyalgia-related symptom severity. Stress Health 32:503–513.  https://doi.org/10.1002/smi.2648 Google Scholar
  31. 31.
    Kiguchi N, Kobayashi Y, Kishioka S (2012) Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 12:55–61.  https://doi.org/10.1016/j.coph.2011.10.007 Google Scholar
  32. 32.
    Furer V, Hazan E, Mor A, Segal M, Katav A, Aloush V, Elkayam O, George J, Ablin JN (2018) Elevated levels of eotaxin-2 in serum of fibromyalgia patients. Pain Res Manag 2018:7257681.  https://doi.org/10.1155/2018/7257681 Google Scholar
  33. 33.
    Wallace DJ, Gavin IM, Karpenko O, Barkhordar F, Gillis BS (2015) Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis. Rheumatol Int 35:991–996.  https://doi.org/10.1007/s00296-014-3172-2 Google Scholar
  34. 34.
    Bäckryd E, Tanum L, Lind AL, Larsson A, Gordh T (2017) Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J Pain Res 10:515–525.  https://doi.org/10.2147/JPR.S128508 Google Scholar
  35. 35.
    Geiss A, Rohleder N, Anton F (2012) Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 37:671–684.  https://doi.org/10.1016/j.psyneuen.2011.07.021 Google Scholar
  36. 36.
    Wright HL, Moots RJ, Bucknall RC, Edwards SW (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49:1618–1631.  https://doi.org/10.1093/rheumatology/keq045 Google Scholar
  37. 37.
    Aktürk S, Büyükavcı R (2017) Evaluation of blood neutrophil-lymphocyte ratio and platelet distribution width as inflammatory markers in patients with fibromyalgia. Clin Rheumatol 36:1885–1889.  https://doi.org/10.1007/s10067-017-3647-0 Google Scholar
  38. 38.
    Al-Nimer MSM, Mohammad TAM (2018) Correlation of hematological indices and ratios derived from them with FIQR scores in fibromyalgia. Pak J Med Sci 34:1219–1224.  https://doi.org/10.12669/pjms.345.15169 Google Scholar
  39. 39.
    Mertoglu C, Gunay M, Yerligok O (2018) Could endocan, a marker of inflammation and endothelial dysfunction, be a new diagnostic marker for fibromyalgia? Clin Lab 64:405–410.  https://doi.org/10.7754/Clin.Lab.2017.171024 Google Scholar
  40. 40.
    Sturgeon JA, Darnall BD, Zwickey HL, Wood LJ, Hanes DA, Zava DT, Mackey SC (2014) Proinflammatory cytokines and DHEA-S in women with fibromyalgia: impact of psychological distress and menopausal status. J Pain Res 7:707–716.  https://doi.org/10.2147/JPR.S71344 Google Scholar
  41. 41.
    Bokarewa MI, Erlandsson MC, Bjersing J, Dehlin M, Mannerkorpi K (2014) Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia. Mediators Inflamm 2014:627041.  https://doi.org/10.1155/2014/627041 Google Scholar
  42. 42.
    Paiva ES, Andretta A, Batista ED, Lobo MMMT, Miranda RC, Nisihara R, Schieferdecker MEM, Boguszewski CL (2017) Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity. Arch Endocrinol Metab 61:249–256.  https://doi.org/10.1590/2359-3997000000248 Google Scholar
  43. 43.
    Bordoni B, Marelli F, Morabito B, Cavallaro F, Lintonbon D (2018) Fascial preadipocytes: another missing piece of the puzzle to understand fibromyalgia? Open Access Rheumatol 10:27–32.  https://doi.org/10.2147/OARRR.S155919 Google Scholar
  44. 44.
    Ataoglu S, Ankarali H, Samanci R, Ozsahin M, Admis O (2018) The relationship between serum leptin level and disease activity and inflammatory markers in fibromyalgia patients N Clin Istanb 5:102–108.  https://doi.org/10.14744/nci.2017.31644 Google Scholar
  45. 45.
    Olama SM, Elsaid TO, El-Arman M (2013) Serum leptin in Egyptian patients with fibromyalgia syndrome: relation to disease severity. Int J Rheum Dis 16:583–589.  https://doi.org/10.1111/1756-185X.12155 Google Scholar
  46. 46.
    Ablin JN, Aronov N, Shimon I, Kanety H, Pariente C, Aloush V, Elkayam O, Levartovsky D (2012) Evaluation of leptin levels among fibromyalgia patients before and after three months of treatment, in comparison with healthy controls. Pain Res Manag 17:89–92Google Scholar
  47. 47.
    Stensson N, Ghafouri B, Gerdle B, Ghafouri N (2017) Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain—a case control study. Lipids Health Dis 16:112.  https://doi.org/10.1186/s12944-017-0505-7 Google Scholar
  48. 48.
    McGarry T, Biniecka M, Veale DJ, Fearon U (2018) Hypoxia, oxidative stress and inflammation. Free Radic Biol Med 125:15–24.  https://doi.org/10.1016/j.freeradbiomed.2018.03.042 Google Scholar
  49. 49.
    Fais A, Cacace E, Atzori L, Era B, Ruggiero V (2017) Plasma phospholipase, γ-CEHC and antioxidant capacity in fibromyalgia. Int J Rheum Dis 20:550–554.  https://doi.org/10.1111/1756-185X.12787 Google Scholar
  50. 50.
    Alcocer-Gómez E, Garrido-Maraver J, Bullón P, Marín-Aguilar F, Cotán D, Carrión AM, Alvarez-Suarez JM, Giampieri F, Sánchez-Alcazar JA, Battino M, Cordero MD (2015) Metformin and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from Fibromyalgia patients. Biochim Biophys Acta 1852:1257–1267.  https://doi.org/10.1016/j.bbadis.2015.03.005 Google Scholar
  51. 51.
    Cordero MD, Díaz-Parrado E, Carrión AM, Alfonsi S, Sánchez-Alcazar JA, Bullón P, Battino M, de Miguel M (2013) Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? Antioxid Redox Signal 18:800–807.  https://doi.org/10.1089/ars.2012.4892 Google Scholar
  52. 52.
    Caboni P, Liori B, Kumar A, Santoru ML, Asthana S, Pieroni E, Fais A, Era B, Cacace E, Ruggiero V, Atzori L (2014) Metabolomics analysis and modeling suggest a lysophosphocholines-PAF receptor interaction in fibromyalgia. PLoS One 9:e107626.  https://doi.org/10.1371/journal.pone.0107626 Google Scholar
  53. 53.
    Bullón P, Alcocer-Gómez E, Carrión AM, Marín-Aguilar F, Garrido-Maraver J, Román-Malo L, Ruiz-Cabello J, Culic O, Ryffel B, Apetoh L, Ghiringhelli F, Battino M, Sánchez-Alcazar JA, Cordero MD (2016) AMPK phosphorylation modulates pain by activation of NLRP3 inflammasome. Antioxid Redox Signal 24:157–170.  https://doi.org/10.1089/ars.2014.6120 Google Scholar
  54. 54.
    Sánchez -Domínguez B, Bullón P, Román-Malo L, Marín-Aguilar F, Alcocer-Gómez E, Carrión AM, Sánchez-Alcazar JA, Cordero MD (2015) Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Mitochondrion 21:69–75.  https://doi.org/10.1016/j.mito.2015.01.010 Google Scholar
  55. 55.
    Gerdle B, Ghafouri B, Ghafouri N, Bäckryd E, Gordh T (2017) Signs of ongoing inflammation in female patients with chronic widespread pain: a multivariate, explorative, cross-sectional study of blood samples. Medicine (Baltimore) 96:e6130.  https://doi.org/10.1097/MD.0000000000006130 Google Scholar
  56. 56.
    Haliloğlu S, Carlioglu A, Sahiner E, Karaaslan Y, Kosar A (2014) Mean platelet volume in patients with fibromyalgia. Z Rheumatol 73:742–745.  https://doi.org/10.1007/s00393-013-1330-7 Google Scholar
  57. 57.
    Feinberg T, Sambamoorthi U, Lilly C, Innes KK (2017) Potential mediators between fibromyalgia and c-reactive protein: results from a large US Community Survey. BMC Musculoskelet Disord 18:294.  https://doi.org/10.1186/s12891-017-1641-y Google Scholar
  58. 58.
    Metyas SK, Solyman JS, Arkfeld DG (2015) Inflammatory fibromyalgia: is it real? Curr Rheumatol Rev 11:15–17.  https://doi.org/10.2174/1573397111666150522095004 Google Scholar
  59. 59.
    Rus A, Molina F, Gassó M, Camacho MV, Peinado M, del Moral ML (2016) Nitric oxide, inflammation, lipid profile, and cortisol in normal- and overweight women with fibromyalgia. Biol Res Nurs 18:138–146.  https://doi.org/10.1177/1099800415591035 Google Scholar
  60. 60.
    Younger J, Noor N, McCue R, Mackey S (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65:529–538.  https://doi.org/10.1002/art.37734 Google Scholar
  61. 61.
    Parkitny L, Younger J (2017) Reduced pro-inflammatory cytokines after 8 weeks of low-dose naltrexone for fibromyalgia. Biomedicines 5:E16.  https://doi.org/10.3390/biomedicines5020016 Google Scholar
  62. 62.
    Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S (2015) Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther 4:169–178.  https://doi.org/10.1007/s40122-015-0038-6 Google Scholar
  63. 63.
    Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76:318–328.  https://doi.org/10.1136/annrheumdis-2016-209724 Google Scholar
  64. 64.
    Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 136:386–392.  https://doi.org/10.1016/j.jad.2011.11.016 Google Scholar
  65. 65.
    Natelson BH, Vu D, Mao X, Weiduschat N, Togo F, Lange G, Blate M, Kang G, Coplan JD, Shungu DC (2015) Effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Pain 16:1211–1219.  https://doi.org/10.1016/j.jpain.2015.08.004 Google Scholar
  66. 66.
    Vasquez A (2016) Neuroinflammation in fibromyalgia and CRPS is multifactorial. Nat Rev Rheumatol 12:242.  https://doi.org/10.1038/nrrheum.2016.25 Google Scholar
  67. 67.
    Senna MK, Sallam RA, Ashour HS, Elarman M (2012) Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial. Clin Rheumatol 31:1591–1597.  https://doi.org/10.1007/s10067-012-2053-x Google Scholar
  68. 68.
    Bettoni L, Bonomi FG, Zani V, Manisco L, Indelicato A, Lanteri P, Banfi G, Lombardi G (2013) Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients. Clin Rheumatol 32:1337–1345.  https://doi.org/10.1007/s10067-013-2280-9 Google Scholar
  69. 69.
    Maeda T, Kudo Y, Horiuchi T, Makino N (2018) Clinical and anti-aging effect of mud-bathing therapy for patients with fibromyalgia. Mol Cell Biochem 444:87–92.  https://doi.org/10.1007/s11010-017-3233-4 Google Scholar
  70. 70.
    Bazzichi L, Da Valle Y, Rossi A, Giacomelli C, Sernissi F, Giannaccini G, Betti L, Ciregia F, Giusti L, Scarpellini P, Dell’Osso L, Marazziti D, Bombardieri S, Lucacchini A (2013) A multidisciplinary approach to study the effects of balneotherapy and mud-bath therapy treatments on fibromyalgia. Clin Exp Rheumatol 31(6 Suppl 79):S111–S120Google Scholar
  71. 71.
    Davis MC, Zautra AJ (2013) An online mindfulness intervention targeting socioemotional regulation in fibromyalgia: results of a randomized controlled trial. Ann Behav Med 46:273–284.  https://doi.org/10.1007/s12160-013-9513-7 Google Scholar
  72. 72.
    Amutio A, Franco C, Pérez-Fuentes Mde C, Gázquez JJ, Mercader I (2015) Mindfulness training for reducing anger, anxiety, and depression in fibromyalgia patients. Front Psychol 5:1572.  https://doi.org/10.3389/fpsyg.2014.01572 Google Scholar
  73. 73.
    Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA (2012) Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. PLoS One 7:e35677.  https://doi.org/10.1371/journal.pone.0035677 Google Scholar
  74. 74.
    Cordero MD, Alcocer-Gómez E, Culic O, Carrión AM, de Miguel M, Díaz-Parrado E, Pérez-Villegas EM, Bullón P, Battino M, Sánchez-Alcazar JA (2014) NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10. Antioxid Redox Signal 20:1169–1180.  https://doi.org/10.1089/ars.2013.5198 Google Scholar
  75. 75.
    Sánchez A, Calpena AC, Clares B (2015) Evaluating the oxidative stress in inflammation: role of melatonin. Int J Mol Sci 16:16981–17004.  https://doi.org/10.3390/ijms160816981 Google Scholar
  76. 76.
    de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, Xavier F, de Souza IC, Deitos A, Torres IL, Caumo W (2014) Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 15:40.  https://doi.org/10.1186/2050-6511-15-40 Google Scholar
  77. 77.
    Efrati S, Golan H, Bechor Y, Faran Y, Daphna-Tekoah S, Sekler G, Fishlev G, Ablin JN, Bergan J, Volkov O, Friedman M, Ben-Jacob E, Buskila D (2015) Hyperbaric oxygen therapy can diminish fibromyalgia syndrome-prospective clinical trial. PLoS One 10:e0127012.  https://doi.org/10.1371/journal.pone.0127012 Google Scholar
  78. 78.
    Bjersing JL, Dehlin M, Erlandsson M, Bokarewa MI, Mannerkorpi K (2012) Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides. Arthritis Res Ther 14:R162.  https://doi.org/10.1186/ar3902 Google Scholar
  79. 79.
    Bjersing JL, Larsson A, Palstam A, Ernberg M, Bileviciute-Ljungar I, Löfgren M, Gerdle B, Kosek E, Mannerkorpi K (2017) Benefits of resistance exercise in lean women with fibromyalgia: involvement of IGF-1 and leptin. BMC Musculoskelet Disord 18:106.  https://doi.org/10.1186/s12891-017-1477-5 Google Scholar
  80. 80.
    Bote ME, Garcia JJ, Hinchado MD, Ortega E (2013) Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise. PLoS One 8:e74524.  https://doi.org/10.1371/journal.pone.0074524 Google Scholar
  81. 81.
    Torgrimson-Ojerio B, Ross RL, Dieckmann NF, Avery S, Bennett RM, Jones KD, Guarino AJ, Wood LJ (2014) Preliminary evidence of a blunted anti-inflammatory response to exhaustive exercise in fibromyalgia. J Neuroimmunol 277:160–167.  https://doi.org/10.1016/j.jneuroim.2014.10.003 Google Scholar
  82. 82.
    Bote ME, García JJ, Hinchado MD, Ortega E (2014) An exploratory study of the effect of regular aquatic exercise on the function of neutrophils from women with fibromyalgia: role of IL-8 and noradrenaline. Brain Behav Immun 39:107–112.  https://doi.org/10.1016/j.bbi.2013.11.009 Google Scholar
  83. 83.
    Ortega E, Bote ME, Giraldo E, García JJ (2012) Aquatic exercise improves the monocyte pro- and anti-inflammatory cytokine production balance in fibromyalgia patients. Scand J Med Sci Sports 22:104–112.  https://doi.org/10.1111/j.1600-0838.2010.01132.x Google Scholar
  84. 84.
    Ernberg M, Christidis N, Ghafouri B, Bileviciute-Ljungar I, Löfgren M, Bjersing J, Palstam A, Larsson A, Mannerkorpi K, Gerdle B, Kosek E (2018) Plasma Cytokine levels in fibromyalgia and their response to 15 weeks of progressive resistance exercise or relaxation therapy. Mediators Inflamm 2018:3985154.  https://doi.org/10.1155/2018/3985154 Google Scholar
  85. 85.
    Ribeiro VGC, Mendonça VA, Souza ALC, Fonseca SF, Camargos ACR, Lage VKS, Neves CDC, Santos JM, Teixeira LAC, Vieira ELM, Teixeira Junior AL, Mezêncio B, Fernandes JSC, Leite HR, Poortmans JR, Lacerda ACR (2018) Inflammatory biomarkers responses after acute whole body vibration in fibromyalgia. Braz J Med Biol Res 51:e6775.  https://doi.org/10.1590/1414-431X20176775 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Physical Medicine and RehabilitationCukurova University Faculty of MedicineAdanaTurkey

Personalised recommendations